A study by researchers at Yale Cancer Center demonstrated that enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.
ASCO, Friends of Cancer Research recommend broadening eligibility criteria in cancer clinical trials
The American Society of Clinical Oncology and Friends of Cancer Research jointly issued recommendations to broaden eligibility criteria in cancer clinical trials, with the goal of making clinical trials more accessible to patients.
Rice University researchers have discovered a genome editing tool that targets the supporting players in a cell's nucleus that package DNA and aid gene expression.
More than half (56.4%) of cancer survivors in the United States reported having additional underlying medical conditions associated with severe COVID-19 illness.
A combination of genetic mutations may explain the higher incidence of and poorer outcomes from pediatric leukemia in Hispanic and Latino children, according to Penn State College of Medicine researchers.
Researchers from the Patrick G Johnston Centre for Cancer Research at Queen's University Belfast are leading an international consortium that aims to determine better ways to treat patients diagnosed with the earliest stages of bowel cancer.
Researchers at Yale Cancer Center have discovered a novel metabolic gatekeeper mechanism for leukemia.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how breast cancer cells hide from immune cells to stay alive. The discovery could lead to better immunotherapy treatment for patients.
For patients with cancers that do not respond to immunotherapy drugs, adjusting the composition of the gut microbiome through the use of stool, or fecal, transplants may help some of these individuals respond to the immunotherapy drugs.
A targeted RNA nanoparticle designed to carry a chemotherapy drug along with a therapeutic oligonucleotide against chemical efflux gene might provide an effective treatment for liver cancer, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.